A Medical Device Daily

GeneNews (Toronto) a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, reported that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle. U.S. Patent number 7,662,558, titled "Method of profiling gene expression in a human subject." The patent covers the application of the Sentinel Principle in any health management context, including diagnosis, staging of disease, drug testing, monitoring response to treatment and biomarker screening.

The Sentinel Principle, a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body.

This technology is the basis of GeneNews' initial product, ColonSentry. ColonSentry was launched in Canada in 2008 and is poised to enter the New York and New Jersey markets in the second half of 2010 through GeneNews' exclusive partnership for these U.S. states with Enzo Clinical Labs. GeneNews said its patent portfolio includes pending patents related to these foundational patents in diverse disease areas such as cancer, cardiovascular, neurological and inflammatory conditions.